Algynomics offers a unique blend of pre-clinical services that enable customers to screen potential analgesics as well as identify novel therapeutic targets. Screening of compounds can be performed in existing well-characterized animal models as well as newly developed animal models tailored towards a specific pain condition or intermediate phenotype. Identification of novel targets can be performed in genetically engineered or pharmacologically challenged animals. Additionally, molecular biologic services targeted towards assessing alterations in gene and/or protein expression associated with alterations in pain behavior following experimental manipulation (e.g., drug delivery or gene knockout) are available. By integrating customized animal model design, superior pain phenotyping, and quality molecular biologic services, Algynomics will support your drug development efforts.
For Researchers
Rodent Pain Phenotyping and Molecular Profiling
Quantification of both elicited and non-elicited pain behaviors as well as related behaviors can be performed. Additionally, biologic tissues and fluids can be collected for molecular profiling analysis.
For Pharma
Pre-clinical Screening of Pain Therapeutics
Various animal models that portray features relevant to human persistent pain phenotypes can be used to screen potential pain therapeutics for analgesic efficacy and side-effects.
Quality Rodent Biologic Specimens
Access to hard-to-obtain biologic specimens allows researchers to plan experiments with reduced time, effort, and expense. Algynomics offers an array of fixed and unfixed tissues (brain, spinal cord, and hind paw) as well as biologic fluids (cerebrospinal fluid, whole blood, plasma, and red blood cells) collected from control and experimental animals. For a subgroup of samples, purified RNA is also available.